RxDoctor Payments Data

Lynn Baru, MD

Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1972529055

Payments from drug & device makers

$6,103in general payments, 2019–2025

Across 120 payments — averaging $50.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$4K
  • Tandem Diabetes Care, Inc.$312
  • AstraZeneca$239
  • Novo Nordisk$181
  • Amgen$159
  • Insulet Corporation$152
  • plus $844 from 19 others
$1,197in research payments, 2019–2025

Across 18 payments — averaging $66.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K

What the payments were for

  • Consulting fees$2,25037%
  • Speaking & faculty fees$2504%
  • Travel & lodging$1,53125%
  • Food & beverage$2,07234%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,103 in reported general payments places this provider in the 65th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina

Medicare billing

Part B allowed, 2024
$8,469
Medicare patients
33
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$84,780
JardianceEmpagliflozin55$33,821
TrulicityDulaglutide16$14,716
Tresiba Flextouch U-100Insulin Degludec23$11,570
Novolog FlexpenInsulin Aspart36$6,834
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,284
SynthroidLevothyroxine Sodium46$2,507
Rosuvastatin Calcium16$2,135
Metformin Hcl ErMetformin Hcl23$357
Nitroglycerin PatchNitroglycerin13$254
Atorvastatin Calcium33$153
Metoprolol Succinate19$106
Metformin Hcl16$53
Simvastatin11$32
Lisinopril27$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$181$84,78084 claims
Boehringer IngelheimJardiance$99$33,82155 claims
Lilly USA, LLCTrulicity$138$14,71616 claims
AbbVieSynthroid$54$2,50746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

Other endocrinology, diabetes & metabolism in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →